Karyopharm Therapeutics-JPM-20240110.pdf

《Karyopharm Therapeutics-JPM-20240110.pdf》由会员分享，可在线阅读，更多相关《Karyopharm Therapeutics-JPM-20240110.pdf（39页珍藏版）》请在三个皮匠报告上搜索。

1、12023 KARYOPHARM THERAPEUTICS INC.JP MORGAN 2024 HEALTHCARE CONFERENCE January 10,2024A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies22023 KARYOPHARM THERAPEUTICS INC.Richard PaulsonChief Executive OfficerOVERVIEW32024 KARYOPHARM THERAPEUTICS INC.This presentation contain

2、s forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.Such forward-looking statements include those regarding Karyopharmspreliminary financial information for the fourth quarter and full year 2023;Karyopharms expected cash runway;beliefs about the ma

3、rket opportunity and annual peak revenue opportunities for selinexor;the abilityof selinexor or eltanexor to treat patients with multiple myeloma,endometrial cancer,myelofibrosis,myelodysplastic neoplasms,diffuse large B-cell lymphoma,and other diseases;expectations related to futureclinical develop

4、ment and potential regulatory submissions of selinexor or eltanexor;expectations with respect to commercialization efforts;submissions to,and the review and potential approval of selinexor,eltanexor or any of its other product candidates by,regulatory authorities,including the Companys regulatory st

5、rategy,the anticipated availability of data to support such submissions,timing of such submissionsand actions by regulatory authorities and the potential availability of accelerated approval pathways;the expected design of the Companys clinical trials;and the therapeutic potential of and potential c

6、linicaldevelopment plans for Karyopharms product candidates,especially selinexor and eltanexor.Such statements are subject to numerous important factors,risks and uncertainties,many of which are beyondKaryopharms control,that may cause actual events or results to differ materially from Karyopharms c